<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284959</url>
  </required_header>
  <id_info>
    <org_study_id>CBIRB1005-58</org_study_id>
    <nct_id>NCT01284959</nct_id>
  </id_info>
  <brief_title>Different Safety Profile of Risperidone and Paliperidone Extended-release</brief_title>
  <official_title>Different Safety Profile of Risperidone and Paliperidone Extended-release: a Double-blind, Placebo-controlled Trial With Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study was to assess subjective experiences related to secondary
      negative symptoms and cognitive performance in healthy volunteers in response to multiple
      doses of paliperidone ER and risperidone in a double-blind, placebo-controlled trial. Adverse
      events caused by these drugs were also evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A new oral antipsychotic drug, paliperidone extended-release (ER), has recently been
      developed and might represent an innovative approach in the treatment of schizophrenia.
      Paliperidone is 9-hydroxyrisperidone, the chief active metabolite of risperidone. Although
      paliperidone possesses a pharmacological profile very similar to that of its parent compound,
      it has many different pharmacokinetic and pharmacodynamic characteristics compared with
      risperidone (Pani and Marchese, 2009). First, paliperidone ER utilizes an osmotic
      controlled-release oral delivery system (OROS), resulting in a more stable serum
      concentration and reduced likelihood of causing unexpected over- or under-dosages due to
      CYP2D6 genetic variability. Second, paliperidone does not undergo significant hepatic
      metabolism, and the drug is predominantly excreted by the kidney as an unchanged drug;
      whereas risperidone is extensively metabolized by the CYP2D6 hepatic enzyme. Third, the
      off-rate for dissociation from human cloned D2 receptors in tissue culture cells is faster
      for paliperidone (60 s) compared with risperidone (27 min) (Seeman, 2005). Due to its looser
      binding to D2 receptors, paliperidone should be associated with a reduced risk of
      extrapyramidal side effects compared with its parent drug. Fourth, ex vivo studies have
      indicated that paliperidone injections induce relatively smaller H1 occupancy levels in the
      brains of animals when compared with similar dosages of risperidone (Schotte, et al. 1995 and
      1996). This may contribute to a reduced sedative effect and less weight gain secondary to
      paliperidone when compared with risperidone. Finally, paliperidone has no relevant affinity
      toward muscarinic receptors, resulting in the absence of anticholinergic side effects; this
      is another important benefit compared with risperidone (Schotte, et al. 1996). Therefore,
      paliperidone would be the drug of choice in young psychotic patients for whom preservation or
      improvement of cognitive function is critical. All of these properties might be associated
      with improved efficacy and better tolerability of paliperidone ER compared with risperidone.
      In support of this view, recent studies (Canuso, et al. 2008 and 2010) demonstrated that
      switching from risperidone to paliperidone ER resulted in improvements in medication
      satisfaction, Positive and Negative Syndrome Scale (PANSS) (Kay, et al. 1987) score, and
      abbreviated Extrapyramidal Symptoms Rating Scale (Chouinard and Margolese, 2005) score.
      However, to date, no clinical trials have investigated the relative superiority of
      paliperidone ER over risperidone in terms of effects on cognitive function. Recently,
      interest in the negative subjective experiences secondary to antipsychotic medications has
      been renewed, as these experiences are key factors in adherence and clinical outcomes (Awad,
      1993; van Putten and May, 1978). Artaloytia et al. (2006) reported that risperidone induced
      negative symptoms in healthy volunteers, which might be termed secondary negative symptoms.
      Therefore, we hypothesized that paliperidone ER has a better safety profile in terms of
      subjective experiences and cognitive function compared with risperidone. Research on the
      effects of antipsychotic drugs on subjective experiences and cognitive function in patients
      with schizophrenia may be hampered by numerous confounding factors, such as pathological
      features of the illness, patient motivation, or concomitant medications. Investigating the
      effects of antipsychotic drugs in healthy subjects provides a method for controlling these
      variables. Therefore, the main objective of this study was to assess subjective experiences
      related to secondary negative symptoms and cognitive performance in healthy volunteers in
      response to multiple doses of paliperidone ER and risperidone in a double-blind,
      placebo-controlled trial. Adverse events caused by these drugs were also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales</measure>
    <time_frame>baseline and 2hr after third medication</time_frame>
    <description>SANS(Scale for the Assessment of Negative Symptoms), NIDSS(Neuroleptic induced Deficit Syndrome Scale) In NIDSS, the average of number 1 to 5 is blunted affect, the average of number 16 to 20 is avolition, the average of number 6 to 15 is cognition, the average of all score is total.
Minimum of NIDSS(avolition, blunted affect, cognition, total) is -3, maximum is +3.(subscale score and total) '+' is better outcome, '-' is worse outcome. Minimum of SANS-Global score for alogia and blunted affect is 0, Maximum of SANS-Global score for alogia and blunted affect is 5 The higher number is worse outcome. The zeros are measured and Calcuated value This outcome measure is reporting a change between baseline and 2hr after third medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events by Objective Rating Scales and Self Report Scales</measure>
    <time_frame>baseline and 2hr after third medication</time_frame>
    <description>DIEPSS(Drug-Induced Extrapyramidal Symptoms Scale), VAS(Visual analog scale);mental sedation (alert-drowsy, muzzy-clear headed, mentally slow-quick witted, attentive-dreamy), physical sedation (strong-feeble, well coordinated-clumsy, lethargic-energetic, incompetent-proficient), tranquilization (calm-excited, contented-discontented, troubled-tranquil, tense-relaxed), and other types of feelings (happy-sad, antagonistic-amicable, interested-bored, withdrawn-gregarious) Minimum of VAS(Mental sedation score,Physical sedation score,Total score) is 0, Maximum is 10.
VAS-total score is average of all subscale scores. Minimum of DIEPSS is 0, Maximum is 4. The higher number is worse outcome. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 2hr after third medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events by Objective Rating Scales and Self Report Scales</measure>
    <time_frame>baseline and 50hr after third medication</time_frame>
    <description>DIEPSS(Drug-Induced Extrapyramidal Symptoms Scale), VAS(Visual analog scale);mental sedation (alert-drowsy, muzzy-clear headed, mentally slow-quick witted, attentive-dreamy), physical sedation (strong-feeble, well coordinated-clumsy, lethargic-energetic, incompetent-proficient), tranquilization (calm-excited, contented-discontented, troubled-tranquil, tense-relaxed), and other types of feelings (happy-sad, antagonistic-amicable, interested-bored, withdrawn-gregarious) Minimum of VAS is 0, Maximum is 10 Minimum of DIEPSS is 0, Maximum is 4 The higher number is worse outcome. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Cognitive Functioning-1</measure>
    <time_frame>baseline and 50hr after third medication</time_frame>
    <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included a word fluency test. All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications.
Minimum of Wisconsin card sorting test-Category completed is 0, Maximum is 6, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative response and Trials to complete is 0, Maximum is 128, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative error is 0, Maximum is 128, the higher number is worse outcome.
Minimum of Word-fluency test is 0 and no maximum value, the higher number is better outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms Assessment by Objective Rating Scales</measure>
    <time_frame>baseline and 50hr after third medication</time_frame>
    <description>SANS(Scale for the Assessment of Negative Symptoms), NIDSS(Neuroleptic induced Deficit Syndrome Scale) Minimum of NIDSS is -3, maximum of NIDSS is +3. '+' is better outcome, '-' is worse outcome. Minimum of SNAS-Global score is 0, Maximum of SNAS-Global score is 5 The higher number is worse outcome. The zeros are measured and Calcuated value. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Cognitive Functioning-2</measure>
    <time_frame>baseline and 50hr after third medication</time_frame>
    <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included the Stroop test, Trail-Making Test B (TMT B). All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications Minimum of Stroop test is 0, no maximum limit, the higher number is worse outcome.
Minimum of Trail making test B is 0 and no maximum limit, the higher number is worse outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Cognitive Functioning-3</measure>
    <time_frame>baseline and 50hr after third medication</time_frame>
    <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included Wisconsin Card-Sorting Test (WCST). All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications.
Minimum of Wisconsin card sorting test-Category completed is 0, Maximum is 6, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative response and Trials to complete is 0, Maximum is 128, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Trials to complete first category trials is 0, Maximum is 128 and minimum of Wisconsin card sorting test-Perseverative error is 0, Maximum is 128, the higher number is worse outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after th</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: risperidone 3mg, PO two times Groups: risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug: lactose, PO 3 times group: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paliperidone ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : Paliperidone ER 6mg PO, two times group: paliperidone ER</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>risperidone 3mg, PO, 3 times</description>
    <arm_group_label>risperidone</arm_group_label>
    <other_name>Rispedal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone ER</intervention_name>
    <description>paliperidone ER 6mg, PO,3 times</description>
    <arm_group_label>paliperidone ER</arm_group_label>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>lactose PO, 3times</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-38 years and meet no DSM-IV diagnostic criteria as assessed by using the
             Structured Clinical Interview for DSM-IV, research version

        Exclusion Criteria:

        Anyone who:

          -  Participated in other clinical trials within 30 days from the start of this clinical
             trial or is currently participating in one

          -  Has progressive disease or in unstable medical condition unfit for the trial

          -  Has been diagnosed in psychiatric terms in the past, depends on psychotropic
             substance, or has overdosed or depended on the substance or alcohol (except for coffee
             or tobacco) within 1 month from the trial start

          -  Is suicidal or highly probable of suicides; OR

          -  Has test results considered clinically meaningful
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-chul Chung, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk national university hospital</name>
      <address>
        <city>Chonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <results_first_submitted>February 29, 2012</results_first_submitted>
  <results_first_submitted_qc>September 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2012</results_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Young Chul Chung</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cognitive function</keyword>
  <keyword>subjective experiences</keyword>
  <keyword>neuroleptic-induced deficit syndrome</keyword>
  <keyword>paliperidone extended-release</keyword>
  <keyword>risperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Risperidone</title>
          <description>Drug: risperidone Groups: risperidone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>drug: lactose group: placebo</description>
        </group>
        <group group_id="P3">
          <title>Paliperidone ER</title>
          <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risperidone</title>
          <description>Drug: risperidone Groups: risperidone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>drug: lactose group: placebo</description>
        </group>
        <group group_id="B3">
          <title>Paliperidone ER</title>
          <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.40" spread="2.59"/>
                    <measurement group_id="B2" value="28.08" spread="2.23"/>
                    <measurement group_id="B3" value="30.60" spread="3.27"/>
                    <measurement group_id="B4" value="28.97" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales</title>
        <description>SANS(Scale for the Assessment of Negative Symptoms), NIDSS(Neuroleptic induced Deficit Syndrome Scale) In NIDSS, the average of number 1 to 5 is blunted affect, the average of number 16 to 20 is avolition, the average of number 6 to 15 is cognition, the average of all score is total.
Minimum of NIDSS(avolition, blunted affect, cognition, total) is -3, maximum is +3.(subscale score and total) '+' is better outcome, '-' is worse outcome. Minimum of SANS-Global score for alogia and blunted affect is 0, Maximum of SANS-Global score for alogia and blunted affect is 5 The higher number is worse outcome. The zeros are measured and Calcuated value This outcome measure is reporting a change between baseline and 2hr after third medication.</description>
        <time_frame>baseline and 2hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales</title>
          <description>SANS(Scale for the Assessment of Negative Symptoms), NIDSS(Neuroleptic induced Deficit Syndrome Scale) In NIDSS, the average of number 1 to 5 is blunted affect, the average of number 16 to 20 is avolition, the average of number 6 to 15 is cognition, the average of all score is total.
Minimum of NIDSS(avolition, blunted affect, cognition, total) is -3, maximum is +3.(subscale score and total) '+' is better outcome, '-' is worse outcome. Minimum of SANS-Global score for alogia and blunted affect is 0, Maximum of SANS-Global score for alogia and blunted affect is 5 The higher number is worse outcome. The zeros are measured and Calcuated value This outcome measure is reporting a change between baseline and 2hr after third medication.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDSS-Avolition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.22"/>
                    <measurement group_id="O2" value="-0.28" spread="0.64"/>
                    <measurement group_id="O3" value="-0.66" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIDSS-Blunted Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.74"/>
                    <measurement group_id="O2" value="0.02" spread="0.35"/>
                    <measurement group_id="O3" value="-0.24" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIDSS-Cognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.53"/>
                    <measurement group_id="O2" value="0.02" spread="0.26"/>
                    <measurement group_id="O3" value="-0.38" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIDSS-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.70"/>
                    <measurement group_id="O2" value="-0.06" spread="0.35"/>
                    <measurement group_id="O3" value="-0.42" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SANS-Global score for alogia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.50"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SANS-Global score for blunted affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.50"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.10" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Adverse Events by Objective Rating Scales and Self Report Scales</title>
        <description>DIEPSS(Drug-Induced Extrapyramidal Symptoms Scale), VAS(Visual analog scale);mental sedation (alert–drowsy, muzzy–clear headed, mentally slow–quick witted, attentive–dreamy), physical sedation (strong–feeble, well coordinated–clumsy, lethargic–energetic, incompetent–proficient), tranquilization (calm–excited, contented–discontented, troubled–tranquil, tense–relaxed), and other types of feelings (happy–sad, antagonistic–amicable, interested–bored, withdrawn–gregarious) Minimum of VAS(Mental sedation score,Physical sedation score,Total score) is 0, Maximum is 10.
VAS-total score is average of all subscale scores. Minimum of DIEPSS is 0, Maximum is 4. The higher number is worse outcome. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 2hr after third medication.</description>
        <time_frame>baseline and 2hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Adverse Events by Objective Rating Scales and Self Report Scales</title>
          <description>DIEPSS(Drug-Induced Extrapyramidal Symptoms Scale), VAS(Visual analog scale);mental sedation (alert–drowsy, muzzy–clear headed, mentally slow–quick witted, attentive–dreamy), physical sedation (strong–feeble, well coordinated–clumsy, lethargic–energetic, incompetent–proficient), tranquilization (calm–excited, contented–discontented, troubled–tranquil, tense–relaxed), and other types of feelings (happy–sad, antagonistic–amicable, interested–bored, withdrawn–gregarious) Minimum of VAS(Mental sedation score,Physical sedation score,Total score) is 0, Maximum is 10.
VAS-total score is average of all subscale scores. Minimum of DIEPSS is 0, Maximum is 4. The higher number is worse outcome. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 2hr after third medication.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS-Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="1.82"/>
                    <measurement group_id="O2" value="3.35" spread="1.69"/>
                    <measurement group_id="O3" value="4.11" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS-Mental sedation score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="2.14"/>
                    <measurement group_id="O2" value="3.85" spread="1.82"/>
                    <measurement group_id="O3" value="4.78" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS-Physical sedation score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="1.79"/>
                    <measurement group_id="O2" value="3.23" spread="1.66"/>
                    <measurement group_id="O3" value="4.08" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIEPSS-Bradykinesia score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.52"/>
                    <measurement group_id="O2" value="0.08" spread="0.29"/>
                    <measurement group_id="O3" value="0.20" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Adverse Events by Objective Rating Scales and Self Report Scales</title>
        <description>DIEPSS(Drug-Induced Extrapyramidal Symptoms Scale), VAS(Visual analog scale);mental sedation (alert-drowsy, muzzy-clear headed, mentally slow-quick witted, attentive-dreamy), physical sedation (strong-feeble, well coordinated-clumsy, lethargic-energetic, incompetent-proficient), tranquilization (calm-excited, contented-discontented, troubled-tranquil, tense-relaxed), and other types of feelings (happy-sad, antagonistic-amicable, interested-bored, withdrawn-gregarious) Minimum of VAS is 0, Maximum is 10 Minimum of DIEPSS is 0, Maximum is 4 The higher number is worse outcome. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
        <time_frame>baseline and 50hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Adverse Events by Objective Rating Scales and Self Report Scales</title>
          <description>DIEPSS(Drug-Induced Extrapyramidal Symptoms Scale), VAS(Visual analog scale);mental sedation (alert-drowsy, muzzy-clear headed, mentally slow-quick witted, attentive-dreamy), physical sedation (strong-feeble, well coordinated-clumsy, lethargic-energetic, incompetent-proficient), tranquilization (calm-excited, contented-discontented, troubled-tranquil, tense-relaxed), and other types of feelings (happy-sad, antagonistic-amicable, interested-bored, withdrawn-gregarious) Minimum of VAS is 0, Maximum is 10 Minimum of DIEPSS is 0, Maximum is 4 The higher number is worse outcome. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS-Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="1.27"/>
                    <measurement group_id="O2" value="3.74" spread="1.80"/>
                    <measurement group_id="O3" value="3.42" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS-Mental sedation score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="1.37"/>
                    <measurement group_id="O2" value="4.21" spread="1.87"/>
                    <measurement group_id="O3" value="3.60" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS-Physical sedation score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="1.50"/>
                    <measurement group_id="O2" value="3.69" spread="1.90"/>
                    <measurement group_id="O3" value="3.35" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIEPSS-Bradykinesia score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.46"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.10" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Cognitive Functioning-1</title>
        <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included a word fluency test. All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications.
Minimum of Wisconsin card sorting test-Category completed is 0, Maximum is 6, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative response and Trials to complete is 0, Maximum is 128, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative error is 0, Maximum is 128, the higher number is worse outcome.
Minimum of Word-fluency test is 0 and no maximum value, the higher number is better outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
        <time_frame>baseline and 50hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Cognitive Functioning-1</title>
          <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included a word fluency test. All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications.
Minimum of Wisconsin card sorting test-Category completed is 0, Maximum is 6, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative response and Trials to complete is 0, Maximum is 128, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative error is 0, Maximum is 128, the higher number is worse outcome.
Minimum of Word-fluency test is 0 and no maximum value, the higher number is better outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Word-fluency test-Animal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" spread="9.46"/>
                    <measurement group_id="O2" value="25.42" spread="4.12"/>
                    <measurement group_id="O3" value="23.50" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word-fluency test-Stationery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.56" spread="7.58"/>
                    <measurement group_id="O2" value="26.00" spread="5.24"/>
                    <measurement group_id="O3" value="23.60" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word-fluency test-&quot;ㄱ&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.44" spread="7.68"/>
                    <measurement group_id="O2" value="19.75" spread="4.54"/>
                    <measurement group_id="O3" value="17.10" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word-fluency test-&quot;ㅅ&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.44" spread="5.85"/>
                    <measurement group_id="O2" value="18.25" spread="4.85"/>
                    <measurement group_id="O3" value="16.40" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word-fluency test-&quot;ㅇ&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.11" spread="4.11"/>
                    <measurement group_id="O2" value="17.17" spread="4.73"/>
                    <measurement group_id="O3" value="16.70" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms Assessment by Objective Rating Scales</title>
        <description>SANS(Scale for the Assessment of Negative Symptoms), NIDSS(Neuroleptic induced Deficit Syndrome Scale) Minimum of NIDSS is -3, maximum of NIDSS is +3. '+' is better outcome, '-' is worse outcome. Minimum of SNAS-Global score is 0, Maximum of SNAS-Global score is 5 The higher number is worse outcome. The zeros are measured and Calcuated value. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
        <time_frame>baseline and 50hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms Assessment by Objective Rating Scales</title>
          <description>SANS(Scale for the Assessment of Negative Symptoms), NIDSS(Neuroleptic induced Deficit Syndrome Scale) Minimum of NIDSS is -3, maximum of NIDSS is +3. '+' is better outcome, '-' is worse outcome. Minimum of SNAS-Global score is 0, Maximum of SNAS-Global score is 5 The higher number is worse outcome. The zeros are measured and Calcuated value. The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDSS-Avolition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.70"/>
                    <measurement group_id="O2" value="-0.37" spread="0.72"/>
                    <measurement group_id="O3" value="0.14" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIDSS-Blunted Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.64"/>
                    <measurement group_id="O2" value="-0.27" spread="0.34"/>
                    <measurement group_id="O3" value="0.04" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIDSS-Cognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.57"/>
                    <measurement group_id="O2" value="-0.26" spread="0.39"/>
                    <measurement group_id="O3" value="0.28" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIDSS-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.59"/>
                    <measurement group_id="O2" value="-0.29" spread="0.41"/>
                    <measurement group_id="O3" value="0.19" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SANS-Global score for alogia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SANS-Global score for blunted affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.46"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Cognitive Functioning-2</title>
        <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included the Stroop test, Trail-Making Test B (TMT B). All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications Minimum of Stroop test is 0, no maximum limit, the higher number is worse outcome.
Minimum of Trail making test B is 0 and no maximum limit, the higher number is worse outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
        <time_frame>baseline and 50hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Cognitive Functioning-2</title>
          <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included the Stroop test, Trail-Making Test B (TMT B). All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications Minimum of Stroop test is 0, no maximum limit, the higher number is worse outcome.
Minimum of Trail making test B is 0 and no maximum limit, the higher number is worse outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after third medication.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stroop test-Color</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.40" spread="4.51"/>
                    <measurement group_id="O2" value="13.09" spread="1.67"/>
                    <measurement group_id="O3" value="12.68" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroop test-Word-color</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.84" spread="4.53"/>
                    <measurement group_id="O2" value="17.53" spread="2.97"/>
                    <measurement group_id="O3" value="18.31" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroop test-Interference score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" spread="1.77"/>
                    <measurement group_id="O2" value="4.44" spread="2.01"/>
                    <measurement group_id="O3" value="5.63" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail making test B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.78" spread="10.24"/>
                    <measurement group_id="O2" value="28.42" spread="7.45"/>
                    <measurement group_id="O3" value="31.10" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Cognitive Functioning-3</title>
        <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included Wisconsin Card-Sorting Test (WCST). All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications.
Minimum of Wisconsin card sorting test-Category completed is 0, Maximum is 6, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative response and Trials to complete is 0, Maximum is 128, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Trials to complete first category trials is 0, Maximum is 128 and minimum of Wisconsin card sorting test-Perseverative error is 0, Maximum is 128, the higher number is worse outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after th</description>
        <time_frame>baseline and 50hr after third medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Drug: risperidone Groups: risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>drug: lactose group: placebo</description>
          </group>
          <group group_id="O3">
            <title>Paliperidone ER</title>
            <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Cognitive Functioning-3</title>
          <description>CNT(Computerized Neuro-Cognitive Function Test System); The tests included Wisconsin Card-Sorting Test (WCST). All of the assessments except the CNT were conducted immediately prior to administration of the medication and at 2 (for risperidone and placebo) or 24 h (for paliperidone ER) after the first and third administrations of the study medications.
Minimum of Wisconsin card sorting test-Category completed is 0, Maximum is 6, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Perseverative response and Trials to complete is 0, Maximum is 128, the lower number is worse outcome.
Minimum of Wisconsin card sorting test-Trials to complete first category trials is 0, Maximum is 128 and minimum of Wisconsin card sorting test-Perseverative error is 0, Maximum is 128, the higher number is worse outcome.
The score ranges are for subscale score. This outcome measure is reporting a change between baseline and 50hr after th</description>
          <units>trials</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wisconsin card sorting test-Category completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="0.00"/>
                    <measurement group_id="O2" value="6.00" spread="0.00"/>
                    <measurement group_id="O3" value="6.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wisconsin card sorting test-Perseverative response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.11" spread="6.03"/>
                    <measurement group_id="O2" value="13.08" spread="8.11"/>
                    <measurement group_id="O3" value="10.10" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wisconsin card sorting test-Perseverative error</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="3.50"/>
                    <measurement group_id="O2" value="9.67" spread="6.11"/>
                    <measurement group_id="O3" value="6.50" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WCST-Trials to complete first category trials</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="7.98"/>
                    <measurement group_id="O2" value="11.75" spread="2.01"/>
                    <measurement group_id="O3" value="12.10" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Risperidone</title>
          <description>Drug: risperidone Groups: risperidone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>drug: lactose group: placebo</description>
        </group>
        <group group_id="E3">
          <title>Paliperidone ER</title>
          <description>Drug: Paliperidone ER Groups: Paliperidone ER</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort(vomiting)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size was small, which presents higher risk of a type II error. The time of assessment after administering placebo or risperidone was noon to 2 PM, which may have contributed to the increased reports of sedation</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Youngchul Chung</name_or_title>
      <organization>Chonbuk National University Hospital</organization>
      <phone>+82-63-250-2185</phone>
      <email>chungyc@chonbuk.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

